Evidence map›Paper›PMID 40425576›Full record

ArticleNature communications2025

Soft matrix promotes immunosuppression in tumor-resident immune cells via COX-FGF2 signaling.

Aino Peura, Rita Turpin, Ruixian Liu, Maria Heilala, Maria Salmela, July Aung, Piia Mikkonen, Minna Mutka, Panu E Kovanen, Laura Niinikoski and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. DONSON links tumor-cell survival to MIF-associated macrophage remodeling in small cell lung cancer.Apoptosis : an international journal on programmed cell death · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Aino PeuraCancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Programs Unit, & Medicum, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-8958-940X
Rita Turpin *Cancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Programs Unit, & Medicum, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-5094-5032
Ruixian Liu *Cancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Programs Unit, & Medicum, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-3065-6743
Maria HeilalaDepartment of Applied Physics, Aalto University, Espoo, Finland.ORCID http://orcid.org/0000-0002-4237-4081
Maria SalmelaFinnish Genome Editing Center, HiLIFE infrastructures, University of Helsinki and Biocenter Finland, Helsinki, Finland.
July AungCancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Programs Unit, & Medicum, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-4844-1289
Piia MikkonenUPM Biomedicals, UPM-Kymmene Corporation, Helsinki, Finland.
Minna MutkaDepartment of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-8380-7293
Panu E KovanenDepartment of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
Laura NiinikoskiBreast Surgery Unit, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-0838-2918
Tuomo MeretojaBreast Surgery Unit, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Johanna MattsonComprehensive Cancer Center, University of Helsinki & Helsinki University Hospital, Helsinki, Finland.ORCID http://orcid.org/0000-0002-9719-9110
Päivi HeikkiläDepartment of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
Päivi PalanneDepartment of Surgery, Kymenlaakso Central Hospital, KYMSOTE, Kotka, Finland.
Tiina KantanenDepartment of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
Mikko KilpeläinenDepartment of Surgery, Kymenlaakso Central Hospital, KYMSOTE, Kotka, Finland.
Outi UkkonenDepartment of Surgery, Kymenlaakso Central Hospital, KYMSOTE, Kotka, Finland.
Maija HollménMedicity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, Finland.ORCID http://orcid.org/0000-0002-3250-7653
Topi A TervonenCancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Programs Unit, & Medicum, University of Helsinki, Helsinki, Finland.
Juha KlefströmCancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Programs Unit, & Medicum, University of Helsinki, Helsinki, Finland. juha.klefstrom@helsinki.fi.ORCID http://orcid.org/0000-0001-7124-8431
Pauliina M MunneCancer Cell Circuitry Laboratory, Translational Cancer Medicine Research Program, Research Programs Unit, & Medicum, University of Helsinki, Helsinki, Finland. pauliina.munne@helsinki.fi.ORCID http://orcid.org/0000-0002-9720-9964

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mechanical forces of the tumor microenvironment change dynamically during key events of tumorigenesis such as invasion and metastasis. These changes in compressive forces often affect the breast cancer cell phenotype. However, it is lesser known how these dynamic mechanical forces in the tumor microenvironment affect the phenotypes of tumor infiltrated leukocytes (TIL) and their subsequent anticancer activities. Here we find, in primary patient-derived explant cultures (PDEC) containing resident TILs, that low compression promotes a change in the original identity of breast cancer cells from luminal to a more mesenchymal and undifferentiated state. These altered tumor cells induce an upregulation of immunosuppressive cytokines such as interleukin-10 (IL-10) and Transforming Growth Factor Beta (TGF-β), as well as polarization of macrophages towards pro-tumor M2(Gc)-type and depletion of CD8+ effector memory T-cells. These immunosuppressive events are mediated by tumor cell derived fibroblast growth factor 2 (FGF2) and prostaglandin E2 (PGE2). We also find that FGF2 rich areas in primary tumors show enrichment in M2-like-macrophages and diminished numbers of CD8 + T and B-cells. Our results suggest that low compressive forces in the tumor microenvironment induce local immunosuppression via FGF2 secretion arising from phenotypic plasticity of tumor cells.

Indexed as

Breast NeoplasmsCyclooxygenase 2Fibroblast Growth Factor 2Immune ToleranceLymphocytes, Tumor-InfiltratingB-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorDinoprostoneFemaleHumansInterleukin-10MacrophagesSignal TransductionTransforming Growth Factor betaTumor MicroenvironmentCyclooxygenase 2DinoprostoneFibroblast Growth Factor 2Interleukin-10Transforming Growth Factor beta

Identifiers

PMID40425576
PMCPMC12116891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.